Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Merz Pharmaceuticals GmbH |
---|---|
Information provided by: | Merz Pharmaceuticals GmbH |
ClinicalTrials.gov Identifier: | NCT00955760 |
Primary Objectives:
Secondary Objectives:
Condition | Intervention | Phase |
---|---|---|
Healthy |
Drug: Neramexane |
Phase I |
Study Type: | Interventional |
Study Design: | Open Label |
Official Title: | A Single Center, Open-Label, Three Periods, Fixed Sequence Design Study Analyzing the Effect of Rifampicin Administration on the Pharmacokinetics of Neramexane Mesylate |
Ages Eligible for Study: | 18 Years to 45 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Exclusion Criteria:
Safety concerns
Lack of suitability for the trial
Use of any prescribed medication for four weeks prior to the first administration of IMP.
Germany, Bayern | |
AAIPharma Deutschland gmbH & Co. KG | Recruiting |
Neu-Ulm, Bayern, Germany, 89231 | |
Contact: Michael Lissy 0049 731 98 440 ext 125 michael.lissy@aaipharma.de |
Responsible Party: | AAIPharma Deutschland GmbH & Co. KG ( Michael Lissy ) |
Study ID Numbers: | MRZ 92579/TI/1003 |
Study First Received: | August 6, 2009 |
Last Updated: | September 3, 2009 |
ClinicalTrials.gov Identifier: | NCT00955760 History of Changes |
Health Authority: | Germany: Federal Institute for Drugs and Medical Devices |
Healthy subjects |
Rifampin Healthy |